<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:38:39Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9627260" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9627260</identifier>
        <datestamp>2023-01-05</datestamp>
        <setSpec>aacrsd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer Epidemiol Biomarkers Prev</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer Epidemiol Biomarkers Prev</journal-id>
              <journal-title-group>
                <journal-title>Cancer Epidemiology, Biomarkers &amp; Prevention</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1055-9965</issn>
              <issn pub-type="epub">1538-7755</issn>
              <publisher>
                <publisher-name>American Association for Cancer Research</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9627260</article-id>
              <article-id pub-id-type="pmcid">PMC9627260</article-id>
              <article-id pub-id-type="pmc-uid">9627260</article-id>
              <article-id pub-id-type="pmid">35984985</article-id>
              <article-id pub-id-type="pmid">35984985</article-id>
              <article-id pub-id-type="publisher-id">EPI-22-0320</article-id>
              <article-id pub-id-type="doi">10.1158/1055-9965.EPI-22-0320</article-id>
              <article-version id="ver1" article-version-type="VoR">Version of Record</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Null Results in Brief</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis</article-title>
                <alt-title alt-title-type="short">Polygenic Score of Oxaliplatin Treatment Efficacy</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8055-3729</contrib-id>
                  <name>
                    <surname>Park</surname>
                    <given-names>Hanla A.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7467-6343</contrib-id>
                  <name>
                    <surname>Edelmann</surname>
                    <given-names>Dominic</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4261-4583</contrib-id>
                  <name>
                    <surname>Canzian</surname>
                    <given-names>Federico</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4173-7530</contrib-id>
                  <name>
                    <surname>Harrison</surname>
                    <given-names>Tabitha A.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2114-2975</contrib-id>
                  <name>
                    <surname>Hua</surname>
                    <given-names>Xinwei</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                  <xref rid="aff7" ref-type="aff">7</xref>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4640-8832</contrib-id>
                  <name>
                    <surname>Shi</surname>
                    <given-names>Qian</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2333-8648</contrib-id>
                  <name>
                    <surname>Silverman</surname>
                    <given-names>Allison</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8215-7359</contrib-id>
                  <name>
                    <surname>Schneider</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0308-8223</contrib-id>
                  <name>
                    <surname>Goldberg</surname>
                    <given-names>Richard M.</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5835-4122</contrib-id>
                  <name>
                    <surname>Alberts</surname>
                    <given-names>Steven R.</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8307-3197</contrib-id>
                  <name>
                    <surname>Hoffmeister</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6129-1572</contrib-id>
                  <name>
                    <surname>Brenner</surname>
                    <given-names>Hermann</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                  <xref rid="aff15" ref-type="aff">15</xref>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7284-6767</contrib-id>
                  <name>
                    <surname>Chan</surname>
                    <given-names>Andrew T.</given-names>
                  </name>
                  <xref rid="aff17" ref-type="aff">17</xref>
                  <xref rid="aff18" ref-type="aff">18</xref>
                  <xref rid="aff19" ref-type="aff">19</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5666-9318</contrib-id>
                  <name>
                    <surname>Peters</surname>
                    <given-names>Ulrike</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <xref rid="aff20" ref-type="aff">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8786-0043</contrib-id>
                  <name>
                    <surname>Newcomb</surname>
                    <given-names>Polly A.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <xref rid="aff20" ref-type="aff">20</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8919-1971</contrib-id>
                  <name>
                    <surname>Chang-Claude</surname>
                    <given-names>Jenny</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff21" ref-type="aff">21</xref>
                  <xref rid="cor1" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.</aff>
              <aff id="aff2"><label>2</label>Medical Faculty, University of Heidelberg, Heidelberg, Germany.</aff>
              <aff id="aff3"><label>3</label>Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.</aff>
              <aff id="aff4"><label>4</label>Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.</aff>
              <aff id="aff5"><label>5</label>Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.</aff>
              <aff id="aff6"><label>6</label>Department of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</aff>
              <aff id="aff7"><label>7</label>Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts.</aff>
              <aff id="aff8"><label>8</label>Department of Cardiology, Peking University Third Hospital, Peking University, Beijing, China.</aff>
              <aff id="aff9"><label>9</label>Department of Quantitative Science, Mayo Clinic, Rochester, Minnesota.</aff>
              <aff id="aff10"><label>10</label>Epidemiology Program, Fred Hutchinson Research Cancer Research Center, Seattle, Washington.</aff>
              <aff id="aff11"><label>11</label>Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.</aff>
              <aff id="aff12"><label>12</label>West Virginia University Cancer Institute, Morgantown, West Virginia.</aff>
              <aff id="aff13"><label>13</label>Medical Oncology, Mayo Clinic, Rochester, Minnesota.</aff>
              <aff id="aff14"><label>14</label>Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.</aff>
              <aff id="aff15"><label>15</label>Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.</aff>
              <aff id="aff16"><label>16</label>German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</aff>
              <aff id="aff17"><label>17</label>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</aff>
              <aff id="aff18"><label>18</label>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.</aff>
              <aff id="aff19"><label>19</label>Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.</aff>
              <aff id="aff20"><label>20</label>School of Public Health, University of Washington, Seattle, Washington.</aff>
              <aff id="aff21"><label>21</label>Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</aff>
              <author-notes>
                <corresp id="cor1"><label>*</label><bold>Corresponding Author:</bold> Jenny Chang-Claude, Unit of Genetic Epidemiology, Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Im Neuenheimer Feld 581, Heidelberg 69120, Germany. Phone: 4962-2142-2373; Fax: 4962-2142-2203; E-mail: <email>j.chang-claude@dkfz.de</email></corresp>
                <fn fn-type="other">
                  <p>Cancer Epidemiol Biomarkers Prev 2022;31:2087–91</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub" iso-8601-date="2022-11-02">
                <day>02</day>
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2022-08-19">
                <day>19</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <volume>31</volume>
              <issue>11</issue>
              <fpage>2087</fpage>
              <lpage>2091</lpage>
              <history>
                <date date-type="received" iso-8601-date="2022-04-07">
                  <day>07</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd" iso-8601-date="2022-06-23">
                  <day>23</day>
                  <month>6</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted" iso-8601-date="2022-08-17">
                  <day>17</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>©2022 The Authors; Published by the American Association for Cancer Research</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>American Association for Cancer Research</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="2087.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec>
                  <title>Background:</title>
                  <p>Associations between candidate germline genetic variants and treatment outcome of oxaliplatin, a drug commonly used for patients with colorectal cancer, have been reported but not robustly established. This study aimed to construct polygenic hazard scores (PHSs) as predictive markers for oxaliplatin treatment outcome by using a supervised principal component approach (PCA).</p>
                </sec>
                <sec>
                  <title>Methods:</title>
                  <p>Genome-wide association analysis for overall survival, including interaction terms (SNP*treatment type) was carried out using two phase III trials, 3,098 resected stage III colon cancer (rCC) patients of NCCTG N0147 and 506 metastatic colorectal cancer (mCRC) patients of NCCTG N9741, separately. SNPs showing interaction with genome-wide significance (<italic toggle="yes">P</italic> &lt; 5 × 10<sup>–8</sup>) were selected for PCA to derive a PHS. PHS interaction with treatment was included in Cox regression models to predict outcome. Replication of prediction models was performed in an independent cohort, DACHS.</p>
                </sec>
                <sec>
                  <title>Results:</title>
                  <p>The two PHSs based on the first two principal components of selected SNPs (15SNPs for rCC and 13SNPs for mCRC) were used to construct interaction terms with treatment type and included in models adjusted for clinical covariables. However, in the DACHS study, the addition of the two PHS terms to clinical models did not improve the prediction error in either patients with rCC or mCRC. PHS interaction was also not replicated.</p>
                </sec>
                <sec>
                  <title>Conclusions:</title>
                  <p>The PHSs derived using principal components efficiently combined multiple predictive SNPs for estimating likelihood of benefit from oxaliplatin versus other treatment but could not be replicated.</p>
                </sec>
                <sec>
                  <title>Impact:</title>
                  <p>These results highlight the potential but also challenges in generating evidence for a predictive polygenic score for oxaliplatin efficacy.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>U.S. Public Health Service (USPHS)</institution>
                      <institution-id>https://doi.org/10.13039/100007197</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>CA25224</award-id>
                  <award-id>CA37404</award-id>
                  <award-id>CA35103</award-id>
                  <award-id>CA35113</award-id>
                  <award-id>CA35272</award-id>
                  <award-id>CA114740</award-id>
                  <award-id>CA32102</award-id>
                  <award-id>CA14028</award-id>
                  <award-id>CA49957</award-id>
                  <award-id>CA21115</award-id>
                  <award-id>CA31946</award-id>
                  <award-id>CA180868</award-id>
                  <award-id>CA189867</award-id>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute (NCI)</institution>
                      <institution-id>https://doi.org/10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U10CA180821</award-id>
                  <award-id>CA25224</award-id>
                  <award-id>CA32102</award-id>
                  <award-id>CA38926</award-id>
                  <award-id>CA21115</award-id>
                  <award-id>CA77202</award-id>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute (NCI)</institution>
                      <institution-id>https://doi.org/10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01CA176272</award-id>
                </award-group>
                <award-group id="funding-4">
                  <funding-source>
                    <institution-wrap>
                      <institution>Deutsche Forschungsgemeinschaft (DFG)</institution>
                      <institution-id>https://doi.org/10.13039/501100001659</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>BR1704/6-1</award-id>
                  <award-id>BR1704/6-3</award-id>
                  <award-id>BR1704/6-4</award-id>
                  <award-id>BR1704/6-6</award-id>
                  <award-id>CH117/1-1</award-id>
                  <award-id>BR1704/17-1</award-id>
                  <award-id>HO5117/2-1</award-id>
                </award-group>
                <award-group id="funding-5">
                  <funding-source>
                    <institution-wrap>
                      <institution>Bundesministerium für Bildung und Forschung (BMBF)</institution>
                      <institution-id>https://doi.org/10.13039/501100002347</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>01KH0404</award-id>
                  <award-id>01ER0814</award-id>
                  <award-id>01ER0815</award-id>
                  <award-id>01GL1712</award-id>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="5"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1">
              <title>Introduction</title>
              <p>Oxaliplatin is a platinum drug often given in combination with other anticancer drugs to treat colorectal cancer. None of the previously reported candidate genetic polymorphism with oxaliplatin treatment outcomes has been robustly validated (<xref rid="bib1" ref-type="bibr">1</xref>). Applying a machine-learning approach on 592-gene-sequencing data, a recent study derived a 67-gene signature predictive of oxaliplatin-based treatment efficacy in metastatic colorectal cancer (mCRC; ref. <xref rid="bib2" ref-type="bibr">2</xref>). However, no germline genetic variants are currently available as robust predictive markers, i.e., differential association with outcome according to the type of chemotherapy (e.g., with oxaliplatin versus without oxaliplatin) for clinical practice. To efficiently extract the information value of multiple genetic variants showing significant association, we used a supervised principal components approach (<xref rid="bib3" ref-type="bibr">3</xref>) to construct polygenic hazard scores (PHS) for differential outcomes in colorectal cancer patients receiving oxaliplatin-containing chemotherapy versus others.</p>
            </sec>
            <sec sec-type="methods" id="sec2">
              <title>Materials and Methods</title>
              <p>Details of all studies and inclusion criteria are found in Supplementary Methods. Two phase III trials served as discovery cohorts, including 3,098 resected stage III colon cancer (rCC) patients of N0147, 96% of patients received oxaliplatin-containing regime (<xref rid="bib4" ref-type="bibr">4</xref>), and 506 mCRC patients of N9741, 79% of patients received oxaliplatin-containing regime (ref. <xref rid="bib5" ref-type="bibr">5</xref>; Supplementary Fig. S1). Both studies were led by the North Central Cancer Treatment Group (NCCTG). NCCTG is now part of the Alliance for Clinical Trials in Oncology. All participants provided written informed consent and the studies were approved by the institutional review board of all participating centers in accordance with Declaration of Helsinki.</p>
              <p>All analyses were conducted separately for rCC and mCRC. First, genome-wide association analysis for overall survival (OS) was conducted for each SNP. Cox models included an interaction term of SNP with treatment type (predictive effect). Models were adjusted for age, sex, grade (only for NCCTG N0147), <italic toggle="yes">KRAS</italic> mutation, and the first three principal components (PC) of all tested SNPs. Manhattan plots were used to illustrate the <italic toggle="yes">P</italic> values for 4,695,046 imputed/genotyped SNP interactions with type of treatment across chromosomes (Supplementary Fig. S2). Predictive SNPs with genome-wide significance (<italic toggle="yes">P</italic> &lt; 5 × 10<sup>–8</sup>) were used for principal component analyses (PCA) to derive PHSs separately for rCC and mCRC. The PHSs (composed of selected PCs), treatment type, and interaction terms of each PHS with treatment type were added to clinical models [including age, sex, grade (only for patients rCC), and <italic toggle="yes">KRAS</italic> mutation] to predict outcome.</p>
              <p>We attempted validation of the prediction models based on the discovery cohort using patients of the population-based DACHS study (<xref rid="bib6" ref-type="bibr">6, 7</xref>), separately for 549 patients with rCC and 437 patients with mCRC (Supplementary Fig. S1). The study was approved by ethics committees of the Medical Faculty of the University of Heidelberg and the State Medical Boards of Baden-Wuerttemberg and Rhineland-Palatinate. The prediction error curve for OS comparing the clinical models and prediction models was evaluated using the loss function approach (<xref rid="bib8" ref-type="bibr">8</xref>) in the R package “pec”.</p>
              <sec sec-type="data-availability" id="sec2-1">
                <title>Data availability</title>
                <p>The data from NCCTG N0147 and NCCTG N9741 analyzed in this study are available from dbGaP (phs001290.v1.p1). The data from DACHS study are available on reasonable application from the corresponding author.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec3">
              <title>Results</title>
              <p>Selected characteristics of patients from participating studies according to the type of chemotherapy are presented in Supplementary Table S1. In the discovery cohorts, GWAS yielded 15 significant SNPs for rCC and 13 SNPs for mCRC. PCA of these predictive SNPs revealed a linear combination of the first two PCs as sufficient for an appropriate presentation of their information value, with corresponding weights given in <xref rid="tbl1" ref-type="table">Table 1</xref>. The PHSs, that is, first two PCs of the selected SNPs, were used to construct interaction terms with treatment type. In the discovery cohorts, PHS showed significant interaction with treatment, as expected, because the SNPs were selected for interactions using the same dataset.</p>
              <table-wrap position="float" id="tbl1">
                <label>Table 1.</label>
                <caption>
                  <p>Characteristics of the selected SNPs included into PHS.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Variation rsID</th>
                      <th align="left" rowspan="1" colspan="1">Chr: Position (hg19)</th>
                      <th align="left" rowspan="1" colspan="1">Overlapped Gene</th>
                      <th align="left" rowspan="1" colspan="1">Annotation</th>
                      <th align="left" rowspan="1" colspan="1">Nearest gene</th>
                      <th align="left" rowspan="1" colspan="1">1st eigenvector weight</th>
                      <th align="left" rowspan="1" colspan="1">2nd eigenvector weight</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td colspan="7" align="left" rowspan="1">Resected stage III colon cancer</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs35498763</td>
                      <td align="left" rowspan="1" colspan="1">6:104040991</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1"><italic toggle="yes">SNORA33</italic>, <italic toggle="yes">R3HDM2P2</italic></td>
                      <td align="left" rowspan="1" colspan="1">2.6 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">0.50</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs34110997</td>
                      <td align="left" rowspan="1" colspan="1">6:104043890</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">SNORA33, R3HDM2P2</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">2.6 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">0.50</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs35185174</td>
                      <td align="left" rowspan="1" colspan="1">6:104060351</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">SNORA33, R3HDM2P2</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">2.7 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">0.50</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs71568154</td>
                      <td align="left" rowspan="1" colspan="1">6:104092576</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">SNORA33, R3HDM2P2</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">2.6 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">0.50</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs2893355</td>
                      <td align="left" rowspan="1" colspan="1">7:29804143</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1"><italic toggle="yes">DPY19L2P3</italic>, <italic toggle="yes">WIPF3</italic></td>
                      <td align="left" rowspan="1" colspan="1">1.0 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">−9.06 × 10<sup>–3</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs72733293</td>
                      <td align="left" rowspan="1" colspan="1">9:78627731</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PCSK5</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−1.72 × 10<sup>–3</sup></td>
                      <td align="left" rowspan="1" colspan="1">5.82 × 10<sup>–3</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs7286060</td>
                      <td align="left" rowspan="1" colspan="1">22:25154776</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PIWIL3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.34</td>
                      <td align="left" rowspan="1" colspan="1">1.1 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs8137801</td>
                      <td align="left" rowspan="1" colspan="1">22:25157455</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PIWIL3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.34</td>
                      <td align="left" rowspan="1" colspan="1">1.5 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs11912167</td>
                      <td align="left" rowspan="1" colspan="1">22:25161052</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PIWIL3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.34</td>
                      <td align="left" rowspan="1" colspan="1">1.5 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs76939478</td>
                      <td align="left" rowspan="1" colspan="1">22:25161635</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PIWIL3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.34</td>
                      <td align="left" rowspan="1" colspan="1">1.6 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs78096049</td>
                      <td align="left" rowspan="1" colspan="1">22:25163992</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PIWIL3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.34</td>
                      <td align="left" rowspan="1" colspan="1">1.7 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs112693385</td>
                      <td align="left" rowspan="1" colspan="1">22:25164291</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PIWIL3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.32</td>
                      <td align="left" rowspan="1" colspan="1">2.1 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs111319837</td>
                      <td align="left" rowspan="1" colspan="1">22:25164498</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PIWIL3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.32</td>
                      <td align="left" rowspan="1" colspan="1">2.1 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs75413996</td>
                      <td align="left" rowspan="1" colspan="1">22:25164604</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">PIWIL3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.32</td>
                      <td align="left" rowspan="1" colspan="1">2.1 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs61396473</td>
                      <td align="left" rowspan="1" colspan="1">22:25560990</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">KIAA1671</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">−0.31</td>
                      <td align="left" rowspan="1" colspan="1">2.2 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td colspan="7" align="left" rowspan="1">mCRC</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs17406943</td>
                      <td align="left" rowspan="1" colspan="1">1:56918398</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1"><italic toggle="yes">RP4-710M16.2</italic>, <italic toggle="yes">PPAP2B</italic></td>
                      <td align="left" rowspan="1" colspan="1">8.3 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">−0.49</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs56027745</td>
                      <td align="left" rowspan="1" colspan="1">1:56922419</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">RP4-710M16.2, PPAP2B</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">8.3 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">−0.49</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs74457219</td>
                      <td align="left" rowspan="1" colspan="1">1:56925869</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">RP4-710M16.2, PPAP2B</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">8.3 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">−0.49</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs72662283</td>
                      <td align="left" rowspan="1" colspan="1">1:56926659</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">RP4-710M16.2, PPAP2B</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">8.3 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">−0.49</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs115226504</td>
                      <td align="left" rowspan="1" colspan="1">2:2182286</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">MYT1 L</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">2.1 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">9.0 × 10<sup>–3</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs75318197</td>
                      <td align="left" rowspan="1" colspan="1">2:2186642</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">MYT1L</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">2.1 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">9.0 × 10<sup>–3</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs112014744</td>
                      <td align="left" rowspan="1" colspan="1">7:46713850</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">AC011294.3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Noncoding intronic (splice_site)</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.37</td>
                      <td align="left" rowspan="1" colspan="1">6.6 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs10254077</td>
                      <td align="left" rowspan="1" colspan="1">7:46723871</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">AC011294.3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.38</td>
                      <td align="left" rowspan="1" colspan="1">6.6 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs10282041</td>
                      <td align="left" rowspan="1" colspan="1">7:46735867</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">AC011294.3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Intronic, noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.38</td>
                      <td align="left" rowspan="1" colspan="1">6.5 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs11767153</td>
                      <td align="left" rowspan="1" colspan="1">7:46774786</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">AC011294.3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.38</td>
                      <td align="left" rowspan="1" colspan="1">5.8 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs74362872</td>
                      <td align="left" rowspan="1" colspan="1">7:46788622</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">AC011294.3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.37</td>
                      <td align="left" rowspan="1" colspan="1">6.1 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs75279668</td>
                      <td align="left" rowspan="1" colspan="1">7:46791193</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">AC011294.3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.37</td>
                      <td align="left" rowspan="1" colspan="1">6.1 × 10<sup>–2</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> rs76460164</td>
                      <td align="left" rowspan="1" colspan="1">7:46791195</td>
                      <td align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">AC011294.3</italic>
                      </td>
                      <td align="left" rowspan="1" colspan="1">Noncoding intronic</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.37</td>
                      <td align="left" rowspan="1" colspan="1">6.1 × 10<sup>–2</sup></td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn>
                    <p>Abbreviation: PC, principle component.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The prediction models (model parameters in <xref rid="tbl2" ref-type="table">Table 2</xref>) were not validated in DACHS. The prediction error of the 5-year OS remained unchanged after adding the PHS terms to the clinical models (0.173 in resected stage III colon patients; 0.145 in mCRC patients) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).</p>
              <table-wrap position="float" id="tbl2">
                <label>Table 2.</label>
                <caption>
                  <p>Estimates of clinical model with/without the PHS for overall mortality in patients with resected stage III colon cancer and mCRC in discovery and replication cohorts.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1"/>
                      <th align="center" colspan="4" rowspan="1">Discovery cohort</th>
                      <th align="center" colspan="4" rowspan="1">Replication cohort</th>
                    </tr>
                    <tr>
                      <th align="left" rowspan="1" colspan="1"/>
                      <th align="center" colspan="2" rowspan="1">Model with clinical covariates</th>
                      <th align="center" colspan="2" rowspan="1">Model with clinical covariates and PHS</th>
                      <th align="center" colspan="2" rowspan="1">Model with clinical covariates</th>
                      <th align="center" colspan="2" rowspan="1">Model with clinical covariates and PHS</th>
                    </tr>
                    <tr>
                      <th align="left" rowspan="1" colspan="1">Output</th>
                      <th align="left" rowspan="1" colspan="1">HR (95% CI)</th>
                      <th align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                      </th>
                      <th align="left" rowspan="1" colspan="1">HR (95% CI)</th>
                      <th align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                      </th>
                      <th align="left" rowspan="1" colspan="1">HR (95% CI)</th>
                      <th align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                      </th>
                      <th align="left" rowspan="1" colspan="1">HR (95% CI)</th>
                      <th align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                      </th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td colspan="9" align="left" rowspan="1">In resected stage III colon patients</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Age (per 5-years)</td>
                      <td align="left" rowspan="1" colspan="1">1.09 (1.05–1.13)</td>
                      <td align="left" rowspan="1" colspan="1">6.1 × 10<sup>–6</sup></td>
                      <td align="left" rowspan="1" colspan="1">1.09 (1.05–1.13)</td>
                      <td align="left" rowspan="1" colspan="1">3.4 × 10<sup>–6</sup></td>
                      <td align="left" rowspan="1" colspan="1">1.15 (1.06–1.25)</td>
                      <td align="left" rowspan="1" colspan="1">1.2 × 10<sup>–3</sup></td>
                      <td align="left" rowspan="1" colspan="1">1.15 (1.06–1.26)</td>
                      <td align="left" rowspan="1" colspan="1">1.0 × 10<sup>–3</sup></td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Gender (female)</td>
                      <td align="left" rowspan="1" colspan="1">0.83 (0.71–0.96)</td>
                      <td align="left" rowspan="1" colspan="1">2.0 × 10<sup>–6</sup></td>
                      <td align="left" rowspan="1" colspan="1">0.83 (0.71–0.97)</td>
                      <td align="left" rowspan="1" colspan="1">2.0 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">1.06 (0.78–1.43)</td>
                      <td align="left" rowspan="1" colspan="1">0.70</td>
                      <td align="left" rowspan="1" colspan="1">1.05 (0.78–1.42)</td>
                      <td align="left" rowspan="1" colspan="1">0.73</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Grade (3–4)</td>
                      <td align="left" rowspan="1" colspan="1">1.60 (1.36–1.88)</td>
                      <td align="left" rowspan="1" colspan="1">2.1 × 10<sup>–8</sup></td>
                      <td align="left" rowspan="1" colspan="1">1.63 (1.38–1.92)</td>
                      <td align="left" rowspan="1" colspan="1">5.2 × 10<sup>–9</sup></td>
                      <td align="left" rowspan="1" colspan="1">1.46 (1.07–1.97)</td>
                      <td align="left" rowspan="1" colspan="1">1.5 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">1.44 (0.06–1.96)</td>
                      <td align="left" rowspan="1" colspan="1">0.02</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> KRAS (Wild type)</td>
                      <td align="left" rowspan="1" colspan="1">1.23 (0.92–1.64)</td>
                      <td align="left" rowspan="1" colspan="1">0.16</td>
                      <td align="left" rowspan="1" colspan="1">1.25 (0.93–1.67)</td>
                      <td align="left" rowspan="1" colspan="1">0.14</td>
                      <td align="left" rowspan="1" colspan="1">0.93 (0.63–1.37)</td>
                      <td align="left" rowspan="1" colspan="1">0.72</td>
                      <td align="left" rowspan="1" colspan="1">0.93 (0.63–1.37)</td>
                      <td align="left" rowspan="1" colspan="1">0.72</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Treatment (Oxaliplatin-based)</td>
                      <td align="left" rowspan="1" colspan="1">1.05 (0.74–1.48)</td>
                      <td align="left" rowspan="1" colspan="1">0.79</td>
                      <td align="left" rowspan="1" colspan="1">1.13 (0.76–1.68)</td>
                      <td align="left" rowspan="1" colspan="1">0.53</td>
                      <td align="left" rowspan="1" colspan="1">0.64 (0.44–0.91)</td>
                      <td align="left" rowspan="1" colspan="1">1.4 × 10<sup>–2</sup></td>
                      <td align="left" rowspan="1" colspan="1">0.71 (0.48–1.07)</td>
                      <td align="left" rowspan="1" colspan="1">0.10</td>
                    </tr>
                    <tr>
                      <td colspan="9" align="left" rowspan="1"> PHS:</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">  PC1</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.50 (0.39–0.64)</td>
                      <td align="left" rowspan="1" colspan="1">1.4 × 10<sup>–8</sup></td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.96 (0.82–1.13)</td>
                      <td align="left" rowspan="1" colspan="1">0.63</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">  PC2</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">2.34 (1.78–3.08)</td>
                      <td align="left" rowspan="1" colspan="1">1.3 × 10<sup>–9</sup></td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.99 (0.82–1.18)</td>
                      <td align="left" rowspan="1" colspan="1">0.88</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Treatment*PHS:</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">  PC1</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">2.02 (1.57–2.59)</td>
                      <td align="left" rowspan="1" colspan="1">4.2 × 10<sup>–8</sup></td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">1.22 (0.89–1.69)</td>
                      <td align="left" rowspan="1" colspan="1">0.22</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">  PC2</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.44 (0.33–0.58)</td>
                      <td align="left" rowspan="1" colspan="1">1.5 × 10<sup>–8</sup></td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.93 (0.65–1.32)</td>
                      <td align="left" rowspan="1" colspan="1">0.68</td>
                    </tr>
                    <tr>
                      <td colspan="9" align="left" rowspan="1">In mCRC patients</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Age (per 5-years)</td>
                      <td align="left" rowspan="1" colspan="1">1.01 (0.97–1.05)</td>
                      <td align="left" rowspan="1" colspan="1">0.58</td>
                      <td align="left" rowspan="1" colspan="1">1.01 (0.97–1.05)</td>
                      <td align="left" rowspan="1" colspan="1">0.66</td>
                      <td align="left" rowspan="1" colspan="1">1.04 (0.99–1.09)</td>
                      <td align="left" rowspan="1" colspan="1">0.13</td>
                      <td align="left" rowspan="1" colspan="1">1.04 (0.99–1.09)</td>
                      <td align="left" rowspan="1" colspan="1">0.15</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Gender (Female)</td>
                      <td align="left" rowspan="1" colspan="1">1.02 (0.85–1.23)</td>
                      <td align="left" rowspan="1" colspan="1">0.82</td>
                      <td align="left" rowspan="1" colspan="1">0.99 (0.82–1.19)</td>
                      <td align="left" rowspan="1" colspan="1">0.91</td>
                      <td align="left" rowspan="1" colspan="1">1.08 (0.88–1.33)</td>
                      <td align="left" rowspan="1" colspan="1">0.44</td>
                      <td align="left" rowspan="1" colspan="1">1.09 (0.89–1.34)</td>
                      <td align="left" rowspan="1" colspan="1">0.41</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Treatment (Oxaliplatin-based)</td>
                      <td align="left" rowspan="1" colspan="1">0.70 (0.56–0.88)</td>
                      <td align="left" rowspan="1" colspan="1">2.0 × 10<sup>–3</sup></td>
                      <td align="left" rowspan="1" colspan="1">0.46 (0.36–0.58)</td>
                      <td align="left" rowspan="1" colspan="1">1.8 × 10<sup>–10</sup></td>
                      <td align="left" rowspan="1" colspan="1">0.80 (0.65–1.00)</td>
                      <td align="left" rowspan="1" colspan="1">0.05</td>
                      <td align="left" rowspan="1" colspan="1">0.81 (0.63–1.03)</td>
                      <td align="left" rowspan="1" colspan="1">0.08</td>
                    </tr>
                    <tr>
                      <td colspan="9" align="left" rowspan="1"> PHS:</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">  PC1</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">3.83 (2.58–5.69)</td>
                      <td align="left" rowspan="1" colspan="1">3.1 × 10<sup>–11</sup></td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.96 (0.84–1.10)</td>
                      <td align="left" rowspan="1" colspan="1">0.58</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">  PC2</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">0.69 (0.54–0.88)</td>
                      <td align="left" rowspan="1" colspan="1">3.2 × 10<sup>–3</sup></td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">1.03 (0.90–1.18)</td>
                      <td align="left" rowspan="1" colspan="1">0.69</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> Treatment*PHS:</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">  PC1</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">0.24 (0.16–0.37)</td>
                      <td align="left" rowspan="1" colspan="1">2.0 × 10<sup>–11</sup></td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">0.94 (0.64–1.37)</td>
                      <td align="left" rowspan="1" colspan="1">0.74</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">  PC2</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">1.84 (1.38–2.46)</td>
                      <td align="left" rowspan="1" colspan="1">4.0 × 10<sup>–5</sup></td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">–</td>
                      <td align="left" rowspan="1" colspan="1">1.02 (0.76–1.37)</td>
                      <td align="left" rowspan="1" colspan="1">0.90</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn>
                    <p>Abbreviation: PC, principle component.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig position="float" id="fig1">
                <label>Figure 1.</label>
                <caption>
                  <p>Prediction error curve for overall survival in resected stage III colon patients (<bold>A</bold>), and in metastatic colorectal cancer patients (<bold>B</bold>) in the replication cohort, DACHS study. Red line represents clinical model, and green line represents prediction model after adding the PHS terms to the clinical models).</p>
                </caption>
                <alt-text>Figure 1. Prediction error curve for overall survival in resected stage III colon patients (A), and in metastatic colorectal cancer patients (B) in the replication cohort, DACHS study. Red line represents clinical model, and green line represents prediction model after adding the PHS terms to the clinical models).</alt-text>
                <graphic xlink:href="2087fig1" position="float"/>
              </fig>
              <p>In DACHS, we also failed to replicate the two PHSs and the interaction with treatment in Cox models for OS (<xref rid="tbl2" ref-type="table">Table 2</xref>). Unadjusted Kaplan–Meier curves also showed no difference in OS for patients according to PHSs (Supplementary Fig. S3).</p>
            </sec>
            <sec sec-type="discussion" id="sec4">
              <title>Discussion</title>
              <p>We used an unconventional method to construct predictive PHSs for oxaliplatin treatment outcome for rCC and for mCRC based on genome-wide interaction analysis. However, neither the prediction models nor the PHSs was validated in the independent replication cohort. We cannot rule out that the findings in the discovery cohort were simply due to chance or type I error. The meager discriminative ability of PHS compared to clinical factors may have remained undetected in the replication cohort due to limited power.</p>
              <p>The principal components approach may have limitations when applied to highly correlated SNP data. Therefore, we constructed the classical polygenic score using thresholding and pruning for comparison; however, the prediction did not improve.</p>
              <p>Limitations of the study should be considered when interpreting the results. Discovery cohorts, NCCTG N0147 and NCCTG N9741, were not originally designed to evaluate the efficacy of oxaliplatin. Patients were defined as having received oxaliplatin-based treatment if they were assigned regimens including oxaliplatin. Otherwise, they were considered to have received the other treatment without oxaliplatin. For that reason, only 4% of the patients from the NCCTG N0147 study did not receive the oxaliplatin-based regime, which limits the statistical power to detect interaction with treatment. The patients who did not receive oxaliplatin showed longer OS compared to the patients who received oxaliplatin (Supplementary Table S1). In addition, we were unable to examine tumor response to oxaliplatin using metrics based on tumor size, like early tumor shrinkage or depth of response, which have been shown to be clinical outcomes in metastatic colorectal cancer. OS is, however, one of the widely used end-points in prospective studies to predict long-term survival.</p>
              <p>Strengths of this study include assessing predictive markers (interaction with treatment). Considering that oxaliplatin is not used alone but in association with other chemotherapeutic drugs, prognostic markers from patients who received a combination of oxaliplatin and the other drugs provide limited information on oxaliplatin specifically as a treatment option. Another strength of this study was testing a novel approach to generate PHSs that efficiently combined information from multiple predictive SNPs, thus avoiding the necessity of multiple interaction terms in prediction models for estimating the likelihood of benefit from a particular treatment versus another. Lastly, we accounted for all relevant clinical variables to address the research question on integrating PHS to improve existing clinical models. All analyses were stratified for tumor stage to account for heterogeneity in patient characteristics and corresponding different clinical outcome.</p>
              <p>In conclusion, despite efficiently combining multiple SNPs to predict individual benefit from oxaliplatin-containing treatment the predictive PHSs failed to replicate.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="supp101" position="float" content-type="local-data">
                <label>Supplementary Figure</label>
                <media xlink:href="epi-22-0320_supplementary_methods_table_s1_and_figures_s1-s3_suppsm1_st1_sf1-sf33.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>N0147 was conducted as a collaborative trial of the North Central Cancer Treatment Group (NCCTG), Mayo Clinic, and was supported in part by Public Health Service grants CA25224, CA37404, CA35103, CA35113, CA35272, CA114740, CA32102, CA14028, CA49957, CA21115, CA31946, CA180868, and CA189867 from the National Cancer Institute, Department of Health and Human Services. NCCTG N9741 was supported by National Institutes of Health grants CA25224, CA32102, CA38926, CA21115, and CA77202. The Alliance for Clinical Trials in Oncology was supported by the National Cancer Institute of the National Institutes of Health grant U10CA180821. The DACHS study was supported by grants from the German Research Council (BR1704/6-1z, BR1704/6-3, BR1704/6-4, BR1704/6-6, CH117/1-1, BR1704/17-1, and HO5117/2-1) and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, and 01GL1712). GECCO was supported by the NCI/NIH, USA Department of Health and Human Services, grant R01CA176272.</p>
              <p>The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.</p>
            </ack>
            <fn-group>
              <fn fn-type="supplementary-material">
                <p><bold>Note:</bold> Supplementary data for this article are available at Cancer Epidemiology, Biomarkers &amp; Prevention Online (http://cebp.aacrjournals.org/).</p>
              </fn>
            </fn-group>
            <sec id="sec5">
              <title>Authors' Disclosures</title>
              <p>Q. Shi reports personal fees from Yiviva Inc, grants from Celgene, personal fees from Regeneron Pharmaceuticals, Inc, Hoosier Cancer Research Network, and Chugai Pharmaceutical Co., Ltd; grants from Bristol Myers Squibb/Celgene, Bristol Myers Squibb, Roche/Genentech, and Janssen; and grants from Novartis outside the submitted work. R.M. Goldberg reports personal fees from Taiho, Astra Zeneca, Bayer, G1 Therapeutics, Compass Therapeutics, UpToDate, Eisai, Sorrento Therapeutics, GSK, Merck, Advanced Chemotherapy Technologies, and Innovative Cellular Therapeutics outside the submitted work. H. Brenner reports grants from German Federal Ministry of Education and Research during the conduct of the study. A.T. Chan reports grants and personal fees from Pfizer Inc., personal fees from Bayer Pharma AG and Boehringer Ingelheim, and grants from Zoe Ltd. outside the submitted work. No disclosures were reported by the other authors.</p>
            </sec>
            <sec id="sec6">
              <title>Authors' Contributions</title>
              <p><bold>H.A. Park:</bold> Formal analysis, validation, visualization, methodology, writing–original draft, project administration, writing–review and editing. <bold>D. Edelmann:</bold> Methodology, writing–review and editing. <bold>F. Canzian:</bold> Writing–review and editing. <bold>T.A. Harrison:</bold> Data curation, writing–review and editing. <bold>X. Hua:</bold> Data curation, writing–review and editing. <bold>Q. Shi:</bold> Data curation, writing–review and editing. <bold>A. Silverman:</bold> Data curation. <bold>M. Schneider:</bold> Writing–review and editing. <bold>R.M. Goldberg:</bold> Data curation, writing–review and editing. <bold>S.R. Alberts:</bold> Data curation, writing–review and editing. <bold>M. Hoffmeister:</bold> Data curation, funding acquisition. <bold>H. Brenner:</bold> Data curation, funding acquisition, writing–review and editing. <bold>A.T. Chan:</bold> Data curation. <bold>U. Peters:</bold> Data curation, writing–review and editing. <bold>P.A. Newcomb:</bold> Data curation, writing–review and editing. <bold>J. Chang-Claude:</bold> Conceptualization, data curation, supervision, funding acquisition, methodology, writing–review and editing.</p>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>HA</given-names></string-name>, <string-name><surname>Seibold</surname><given-names>P</given-names></string-name>, <string-name><surname>Edelmann</surname><given-names>D</given-names></string-name>, <string-name><surname>Benner</surname><given-names>A</given-names></string-name>, <string-name><surname>Canzian</surname><given-names>F</given-names></string-name>, <string-name><surname>Alwers</surname><given-names>E</given-names></string-name>,
<etal/></person-group>. <article-title>Validation of genetic markers associated with survival in colorectal cancer patients treated with oxaliplatin-based chemotherapy</article-title>.
<source>Cancer Epidemiol Biomarkers Prev</source><year>2022</year>;<volume>31</volume>:<fpage>352</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">34862210</pub-id></mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abraham</surname><given-names>JP</given-names></string-name>, <string-name><surname>Magee</surname><given-names>D</given-names></string-name>, <string-name><surname>Cremolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Antoniotti</surname><given-names>C</given-names></string-name>, <string-name><surname>Halbert</surname><given-names>DD</given-names></string-name>, <string-name><surname>Xiu</surname><given-names>J</given-names></string-name>,
<etal/></person-group>. <article-title>Clinical validation of a machine-learning-derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer</article-title>.
<source>Clin Cancer Res</source><year>2021</year>;<volume>27</volume>:<fpage>1174</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">33293373</pub-id></mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bair</surname><given-names>E</given-names></string-name>, <string-name><surname>Tibshirani</surname><given-names>R</given-names></string-name></person-group>. <article-title>Semi-supervised methods to predict patient survival from gene expression data</article-title>.
<source>PLoS Biol</source><year>2004</year>;<volume>2</volume>:<fpage>E108</fpage>.<pub-id pub-id-type="pmid">15094809</pub-id></mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alberts</surname><given-names>SR</given-names></string-name>, <string-name><surname>Sargent</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Nair</surname><given-names>S</given-names></string-name>, <string-name><surname>Mahoney</surname><given-names>MR</given-names></string-name>, <string-name><surname>Mooney</surname><given-names>M</given-names></string-name>, <string-name><surname>Thibodeau</surname><given-names>SN</given-names></string-name>,
<etal/></person-group>. <article-title>Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial</article-title>.
<source>JAMA</source><year>2012</year>;<volume>307</volume>:<fpage>1383</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">22474202</pub-id></mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldberg</surname><given-names>RM</given-names></string-name>, <string-name><surname>Sargent</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Morton</surname><given-names>RF</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>CS</given-names></string-name>, <string-name><surname>Ramanathan</surname><given-names>RK</given-names></string-name>, <string-name><surname>Williamson</surname><given-names>SK</given-names></string-name>,
<etal/></person-group>. <article-title>A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer</article-title>.
<source>J Clin Oncol</source><year>2004</year>;<volume>22</volume>:<fpage>23</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">14665611</pub-id></mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brenner</surname><given-names>H</given-names></string-name>, <string-name><surname>Chang-Claude</surname><given-names>J</given-names></string-name>, <string-name><surname>Seiler</surname><given-names>CM</given-names></string-name>, <string-name><surname>Rickert</surname><given-names>A</given-names></string-name>, <string-name><surname>Hoffmeister</surname><given-names>M</given-names></string-name></person-group>. <article-title>Protection from colorectal cancer after colonoscopy: a population-based, case-control study</article-title>.
<source>Ann Intern Med</source><year>2011</year>;<volume>154</volume>:<fpage>22</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">21200035</pub-id></mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brenner</surname><given-names>H</given-names></string-name>, <string-name><surname>Chang-Claude</surname><given-names>J</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>L</given-names></string-name>, <string-name><surname>Knebel</surname><given-names>P</given-names></string-name>, <string-name><surname>Stock</surname><given-names>C</given-names></string-name>, <string-name><surname>Hoffmeister</surname><given-names>M</given-names></string-name></person-group>. <article-title>Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy</article-title>.
<source>Gastroenterology</source><year>2014</year>;<volume>146</volume>:<fpage>709</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">24012982</pub-id></mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gerds</surname><given-names>TA</given-names></string-name>, <string-name><surname>Schumacher</surname><given-names>M</given-names></string-name></person-group>. <article-title>Consistent estimation of the expected Brier score in general survival models with right-censored event times</article-title>.
<source>Biom J</source><year>2006</year>;<volume>48</volume>:<fpage>1029</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">17240660</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
